ARTICLE | Financial News

Cell therapy play Avrobio raises $60M

February 1, 2018 1:13 PM UTC

Avrobio Inc. (Cambridge, Mass.) raised $60 million in a series B round co-led by Cormorant Asset Management and Surveyor Capital. Fellow new investors Aisling, Brace Pharma Capital, Eventide, Morningside and Leerink Partners also participated alongside existing investors Atlas Venture, SV Health Investors and Clarus.

Avrobio is developing cell therapies that are transduced with lentivirus ex vivo to express therapeutic proteins (see BioCentury, Jan. 20, 2017)...

BCIQ Company Profiles

Avrobio Inc.